Skip to main navigation Skip to search Skip to main content

Safety and Efficacy of 1-Month Dual Antiplatelet Therapy (Ticagrelor + Aspirin) Followed by 23-Month Ticagrelor Monotherapy in Patients Undergoing Staged Percutaneous Coronary Intervention (A Sub-Study from GLOBAL LEADERS)

  • Hideyuki Kawashima
  • , Mariusz Tomaniak
  • , Masafumi Ono
  • , Rutao Wang
  • , Hironori Hara
  • , Chao Gao
  • , Kuniaki Takahashi
  • , Faisal Sharif
  • , Attila Thury
  • , Harry Suryapranata
  • , Simon Walsh
  • , James Cotton
  • , Didier Carrie
  • , Manel Sabate
  • , Clemens Steinwender
  • , Gregor Leibundgut
  • , Joanna Wykrzykowska
  • , Robbert J. de Winter
  • , Scot Garg
  • , Christian Hamm
  • Philippe Gabriel Steg, Peter Jüni, Pascal Vranckx, Marco Valgimigli, Stephan Windecker, Yoshinobu Onuma, Patrick W. Serruys
  • University of Amsterdam
  • University of Galway
  • Medical University of Warsaw
  • Radboud University Nijmegen Medical Center
  • University of Szeged
  • Forster Green Hospital
  • New Cross Hospital
  • University Paul Sabatier
  • Hospital Clínic
  • Department of Cardiology Kepler University Hospital Linz Medical Faculty
  • Kantonsspital Baselland
  • Royal Blackburn Hospital
  • Justus-Liebig-University
  • Université Paris Descartes-Sorbonne Paris Cité
  • Royal Brompton Hospital
  • Li Ka Shing Knowledge Institute
  • Hasselt University
  • University Hospital of Psychiatry
  • Imperial College London

Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review

5 Citations (Scopus)

Abstract

Patients undergoing staged percutaneous coronary intervention (SPCI) are exposed to extended duration of antiplatelet therapy, and a novel aspirin-free antiplatelet regimen after SPCI should be specifically evaluated among these patients. This is a prespecified substudy of the GLOBAL LEADERS which is a randomized, open-label trial, comparing an experimental regimen of 1-month dual antiplatelet therapy (DAPT; ticagrelor and aspirin) followed by 23-month ticagrelor monotherapy to a reference regimen of 12-month DAPT followed by 12-month aspirin monotherapy. Patients were stratified according to whether or not SPCI was performed. The impact of the timing of SPCI on clinical outcomes was also investigated. Of 15,968 randomized patients, 1,651 patients underwent SPCI within 3 months. These patients with SPCI had a significantly higher risk of bleeding and ischemic endpoints than those without SPCI. In patients undergoing SPCI, the primary endpoint (composite of all-cause death or new Q-wave myocardial infarction at 2 years) and secondary safety endpoint (Bleeding Academic Research Consortium [BARC]-defined bleeding 3 or 5) were similar in the 2 regimens. However, in patients presenting with acute coronary syndrome (ACS), the experimental regimen reduced a risk of BARC 3 or 5 bleeding (1.8% vs 4.5%; HR 0.387; 95% CI 0.179 to 0.836; p = 0.016). In patients undergoing SPCI later than 10 days after index procedure, this risk reduction was still prominent (0.8% vs 2.3%; HR 0.321; 95% CI 0.116 to 0.891; p = 0.029). In conclusion, patients undergoing SPCI are at high risk and may need special attention from clinicians. In ACS patients undergoing SPCI, a novel aspirin-free antiplatelet regimen appears to be associated with a lower bleeding risk than with standard DAPT.

Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalAmerican Journal of Cardiology
Volume138
DOIs
Publication statusPublished - 1 Jan 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Safety and Efficacy of 1-Month Dual Antiplatelet Therapy (Ticagrelor + Aspirin) Followed by 23-Month Ticagrelor Monotherapy in Patients Undergoing Staged Percutaneous Coronary Intervention (A Sub-Study from GLOBAL LEADERS)'. Together they form a unique fingerprint.

Cite this